Fifth Third Bancorp’s BridgeBio Pharma BBIO Stock Holding History

Fifth Third Bancorp’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.5M	Buy	87,238 +37,509	+75%	+$2.63M	0.01%	656
2026 Q1	$3.69M	Buy	+49,729	New	+$3.6M	0.01%	902
2025 Q4	–	Sell	-30	Closed	-$1.56K	–	2643
2025 Q3	$1.56K	Buy	+30	New	+$1.46K	﹤0.01%	2481
2021 Q2	–	Sell	-100	Closed	-$6K	–	2423
2021 Q1	$6K	Buy	+100	New	+$6.54K	﹤0.01%	2131

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fifth Third Bancorp's BBIO Position: Q2 2026 in Review

Fifth Third Bancorp increased its BridgeBio Pharma (BBIO) stake by 75% in Q2 2026, buying an estimated $2.63M and bringing the position to 87,238 shares worth $6.5M. The position accounts for 0.01% of the portfolio, ranked #656.

Fifth Third Bancorp first reported a position in BBIO in Q1 2021 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Fifth Third Bancorp held 87,238 shares of BridgeBio Pharma worth $6.5M as of Q2 2026.
Fifth Third Bancorp bought 37,509 BridgeBio Pharma shares in Q2 2026, an estimated $2.63M.
BridgeBio Pharma made up 0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #656 holding.
Fifth Third Bancorp first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 4 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.